Article
Infectious Diseases
Xavier Vuillemin, Maelle Da Silvab, Maxime Bour, Celine Landond, Patrick Plesiat, Katy Jeannot
Summary: This study evaluated the impact of certain acquired extended-spectrum oxacillinases (ES-OXA) on the susceptibility of Pseudomonas aeruginosa to cefiderocol. It was found that certain variant ES-OXA significantly decreased the susceptibility of Pseudomonas aeruginosa to cefiderocol.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
(2023)
Editorial Material
Immunology
Ana Paula Streling, Mohanad M. Al Obaidi, William D. Lainhart, Tirdad Zangeneh, Ayesha Khan, An Q. Dinh, Blake Hanson, Cesar A. Arias, William R. Miller
Summary: A study reported the emergence of non-susceptibility to cefiderocol in a subpopulation of Pseudomonas aeruginosa recovered from a patient without prior exposure to the antibiotic. Whole genome sequencing revealed mutations in major iron transport pathways linked to cefiderocol uptake, highlighting the importance of susceptibility testing before therapy with siderophore cephalosporins.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Infectious Diseases
Katie A. Parsels, Keri A. Mastro, Jeffrey M. Steele, Stephen J. Thomas, Wesley D. Kufel
Summary: Cefiderocol is a novel siderophore cephalosporin that has shown activity against clinically relevant MDR Gram-negative bacteria. FDA-approved indications include complicated urinary tract infections and hospital-acquired bacterial pneumonia. Clinical trials have demonstrated non-inferiority to standard treatments, but higher all-cause mortality was observed in certain cases.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
(2021)
Article
Microbiology
Alexandre Bleibtreu, Laurent Dortet, Remy A. Bonnin, Benjamin Wyplosz, Sophie-Caroline Sacleux, Liliana Mihaila, Herve Dupont, Helga Junot, Vincent Bunel, Nathalie Grall, Keyvan Razazi, Clara Duran, Pierre Tattevin, Aurelien Dinh
Summary: Cefiderocol, a novel siderophore cephalosporin, has shown in vitro activity against carbapenem-resistant Gram-negative pathogens and stability towards all carbapenemases. This study in France aimed to describe the first cases of compassionate use of cefiderocol and its efficacy, revealing a need for caution in using orphan drugs during this period; mainly targeting respiratory tract infections.
Editorial Material
Genetics & Heredity
Tatyana L. Povolotsky, Alona Keren-Paz, Ilana Kolodkin-Gal
Summary: For bacteria, the transition from unicellular entities to multicellular biofilm communities generates distinct metabolic microenvironments. Dynamic and programmed metabolic responses allow the biofilms to react to local changes in nutrient levels and contribute to phenotypic antibiotic resistance of the community. Novel therapeutic approaches targeting biofilms may stem from these metabolic adaptations.
TRENDS IN GENETICS
(2021)
Article
Infectious Diseases
Pilar Hernandez-Jimenez, Francisco Lopez-Medrano, Mario Fernandez-Ruiz, J. Tiago Silva, Laura Corbella, Rafael San-Juan, Manuel Lizasoain, Jazmin Diaz-Reganon, Esther Viedma, Jose Maria Aguado
Summary: Risk factors for multidrug-resistant Pseudomonas aeruginosa infection in immunocompromised patients include diabetes mellitus, previous MDR-PSA colonization, prior receipt of antibiotics, and septic shock. These patients have poorer clinical outcomes compared to those infected with non-MDR-PSA strains.
Article
Microbiology
Leilei Wang, Xuefei Zhang, Xun Zhou, Yingmin Bi, Minggui Wang, Qinglan Guo, Fan Yang
Summary: Eleven bla(PER-1)-positive Pseudomonas aeruginosa clinical isolates exhibited variable susceptibility to ceftazidime-avibactam (CZA). The genetic contexts of bla(PER-1) were identical except for one isolate, which showed increased resistance due to an insertion in the upstream region of bla(PER-1). The variability in bla(PER-1) promoter activity partially explains the different susceptibility to CZA in PER-producing isolates.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2023)
Article
Microbiology
Erin K. McCreary, Emily L. Heil, Pranita D. Tamma
Summary: Carbapenem resistance in bacteria is a concerning issue, leading to the development of new antibiotics like cefiderocol. However, conflicting clinical data have left infectious diseases specialists unsure of when to prescribe this novel agent. Research focuses on cefiderocol's role in managing specific pathogens, with summaries of preclinical, clinical trial, and postmarketing data for various organisms to help guide clinical therapeutic decisions.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2021)
Article
Microbiology
Nicholas Teran, Stephanie L. Egge, Kady Phe, Rodrigo P. Baptista, Vincent H. Tam, William R. Miller, Jared A. Silverman
Summary: This study reports a clinical case of cefiderocol-resistant P. aeruginosa and identifies mutations not previously reported, suggesting potential novel pathways to cefiderocol resistance.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2023)
Article
Microbiology
Damien Fournier, Romain Carriere, Maxime Bour, Emilie Grisot, Pauline Triponney, Cedric Muller, Jerome Lemoine, Katy Jeannot, Patrick Plesiat
Summary: This study evaluated the resistance mechanisms of Pseudomonas aeruginosa to ceftolozane/tazobactam, identifying strains with various resistance genes and high production of cephalosporinase PDC. It also found mutations in regulatory genes and enzymes contributing to resistance, highlighting the importance of both intrinsic and transferable mechanisms in C/T-resistant P. aeruginosa.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2021)
Review
Pharmacology & Pharmacy
Yahiya Y. Syed
Summary: Cefiderocol is a cephalosporin with activity against carbapenem-resistant bacteria and nonfermenters, using the bacteria's iron uptake system to disrupt the cell wall and kill the bacteria. It has shown good effectiveness and safety in clinical trials for various serious bacterial infections, providing a useful addition to treatment options for adults with limited choices.
Article
Infectious Diseases
Aiman M. Momenah, Rafat Ahmed Bakri, Naif A. Jalal, Sami S. Ashgar, Rakan Fahad Felemban, Farkad Bantun, Sumyya H. Hariri, Abeer A. Barhameen, Hani Faidah, Hamdi M. AL-Said
Summary: This study evaluates the antibiotic resistance levels of P. aeruginosa and aims to understand the patterns of resistance in clinical isolates. The highest resistance was found in colistin (97%) followed by piperacillin/tazobactam (75.8%). The antibiotic resistance rate decreased in the later years due to infection control protocols and strict antibiotic prescription policies.
INFECTION AND DRUG RESISTANCE
(2023)
Article
Medicine, General & Internal
Andrew Walczak, Kate McCarthy, David L. Paterson
Summary: This retrospective case series analyzed the data of 15 patients with Pseudomonas aeruginosa infective endocarditis. The study aimed to improve the understanding of risk factors, clinical features, treatments, and outcomes. The results showed that all patients presented with fever, with preexisting prosthetic valve and valvular heart disease being the most common risk factors. Healthcare associated infection and left-sided valvular involvement were more common than previously reported. Complications occurred in 11 patients with a 30-day mortality rate of 13%.
Article
Infectious Diseases
Lea Devoos, Adrien Biguenet, Julie Rousselot, Maxime Bour, Patrick Plesiat, Damien Fournier, Katy Jeannot
Summary: This study evaluated the performance of commercially available tests for determining the susceptibility of multidrug-resistant Pseudomonas aeruginosa to cefiderocol. The Sensititre EUMDROXF microplates were found to be an alternative to the reference method, but MIC values +/- 1 dilution apart from the breakpoint (2 mg/L) should be confirmed by the reference method, and the use of MTS gradient strips is not recommended. Disc diffusion may be useful for screening, but many cefiderocol-resistant strains are not detected.
CLINICAL MICROBIOLOGY AND INFECTION
(2023)
Article
Infectious Diseases
Miki Takemura, Mark G. Wise, Meredith A. Hackel, Daniel F. Sahm, Yoshinori Yamano
Summary: This study evaluated the in vitro antibacterial activity of siderophore cephalosporin cefiderocol against MBL-producing clinical isolates. The results showed that cefiderocol exhibited potent in vitro activity against MBL-producing strains of different bacterial species.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
(2023)
